Weidong Han, Ph.D
Biotherapeutic Department, Chinese PLA General Hospital
12
10
0
N/A
0
3
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+10 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (12)
Showing 10 of 12 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Lilin Ye, Ph.D
Department of Tumor Immunology, Changping Laboratory
Shared therapeutic areas:
Worked with same sponsors:
Zhijun Wang, M.D
Department of Interventional radiology, Chinese PLA General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Guanghua Rong, Ph.D
Biotherapeutic Department, the Fifth Medical Center of the PLA General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jianqing Xu, Ph.D
Institutes of Biomedical Sciences, Fudan University
Shared therapeutic areas:
Worked with same sponsors:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Project Leader
Ono Pharmaceutical Co., Ltd.
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Saleh K Saleh, MD
Minia University
Shared therapeutic areas:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (12)
Showing 12 of 12 trials
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors
PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases
All 12 trials loaded